Understanding the Regulatory Framework for Generic Drug Registrations

Pharmaceutical Manufacturer
Pharmaceutical Manufacturer

In Malaysia, the National Pharmaceutical Regulatory Agency (NPRA) enforces strict guidelines for the registration of generic drugs to ensure their safety, efficacy, and quality. The Drug Control Authority (DCA) oversees the process, requiring Bioavailability (BA) and Bioequivalence (BE) studies for oral generic drugs to confirm their therapeutic equivalence to innovator products. This aligns with the ASEAN Guideline for the Conduct of Bioequivalence Studies, which Malaysia officially adopted in March 2015.

Regulatory Requirements for Bioequivalence (BE) Studies

The NPRA Drug Registration Guidance Document (DRGD) mandates BE studies for all generic oral solid dosage forms with systemic action, including both immediate-release and modified-release formulations. These studies ensure that a generic product delivers the same pharmacokinetic profile as the reference product.

Comparator Products in Bioequivalence Studies

For BE studies, applicants must use a comparator product registered with the Drug Control Authority (DCA). The Malaysia Comparator Product (MCP) list, available on the NPRA website, provides approved reference products to ensure consistency in comparative studies.

Approved BE Study Centers in Malaysia

Since January 1, 2012, all BE studies submitted for product registration must be conducted at NPRA-accredited clinical and bioanalytical facilities. These facilities comply with the NPRA BE Centre Compliance Programme, ensuring adherence to international standards for clinical trials.

Malaysian Guideline for Bioequivalence Inspection

The second edition of the Malaysian Guideline for Bioequivalence Inspection, released in September 2024, provides comprehensive instructions for conducting and inspecting BE studies. This ensures that all procedures align with international Good Clinical Practice (GCP) and Good Laboratory Practice (GLP) standards.

ASEAN Common Technical Dossier (ACTD) Format for Drug Registration

The ASEAN Common Technical Dossier (ACTD) is a harmonized format for pharmaceutical product registration across ASEAN member states. It is divided into four main parts:

Part I: Administrative and Product Information

  • Application Form
  • Table of Contents
  • Product Information (Summary of Product Characteristics, Package Insert, Labeling)
  • Good Manufacturing Practice (GMP) Compliance
  • Manufacturing License and Certificate of Pharmaceutical Product (CPP)
  • Patent Declaration (if applicable)
  • Letters of Authorization (if required)

Part II: Quality (Pharmaceutical and Chemical Data)

2.1 General Information

  • Nomenclature (INN, Chemical Name, Structure)
  • Product Description and Composition
  • Pharmaceutical Development Details

2.2 Drug Substance (Active Pharmaceutical Ingredient – API)

  • Manufacturer Details
  • Characterization & Physicochemical Properties
  • Manufacturing Process & Process Controls
  • Analytical Procedures & Stability Data

2.3 Drug Product (Finished Pharmaceutical Product – FPP)

  • Formulation Composition
  • Manufacturing Process and Controls
  • Finished Product Specifications
  • Container & Packaging System
  • Stability Testing Data

Part III: Nonclinical (Safety Data)

  • Pharmacology Studies (Primary & Secondary Pharmacodynamics)
  • Pharmacokinetics (ADME – Absorption, Distribution, Metabolism, Excretion)
  • Toxicology Studies (Acute, Chronic, Mutagenicity, Genotoxicity, Carcinogenicity)

Part IV: Clinical (Efficacy & Safety Data)

  • Clinical Pharmacology (BA/BE Studies)
  • Pivotal Clinical Trials & Comparative Effectiveness Studies
  • Adverse Event Reports & Risk Assessment
  • Pharmacovigilance & Post-Marketing Surveillance

Role of Taj Pharma in Generic Drug Registration in Malaysia

Taj Pharma India Ltd. is a globally recognized pharmaceutical company specializing in generic drug development, manufacturing, and regulatory support. With state-of-the-art WHO-GMP, PICS, and EU-GMP certified facilities, Taj Pharma ensures compliance with Malaysia’s NPRA and ASEAN regulations.

Taj Pharma’s Manufacturing Capabilities

Our Sarigam GIDC manufacturing facility in India boasts advanced production capacities, including:

  • Tablets: 120 million per month
  • Capsules: 40 million per month
  • Dry Blended Powders/Granules: 36,000kg per month
  • Effervescent Tablets: 20 million per month
  • Oral Jelly: 60 million per month
  • Creams & Ointments: 40 million per month
  • Oral Sachets: 3 million per month

Regulatory & Import Support for Malaysian Market

Taj Pharma provides comprehensive regulatory assistance, including:

  • Bioequivalence study facilitation through accredited research centers
  • Dossier preparation in ACTD format for seamless registration
  • Regulatory consultancy services to ensure compliance with NPRA requirements
  • Quality assurance with full GMP, GLP, and ICH compliance

Generic drug registration in Malaysia requires adherence to stringent regulatory processes, particularly in BA/BE studies and ACTD dossier submission. With NPRA-accredited facilities and ASEAN harmonization, the Malaysian pharmaceutical market ensures safe, effective, and high-quality generic medications. Companies like Taj Pharma play a crucial role in facilitating regulatory compliance and importation, making Malaysia a key market for high-quality generics.

Read More: